Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,075 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.
Cammann C, Kulla J, Wiebusch L, Walz C, Zhao F, Lowinus T, Topfstedt E, Mishra N, Henklein P, Bommhardt U, Bossaller L, Hagemeier C, Schadendorf D, Schmidt B, Paschen A, Seifert U. Cammann C, et al. Among authors: schadendorf d. Biomed Pharmacother. 2023 Dec;168:115635. doi: 10.1016/j.biopha.2023.115635. Epub 2023 Oct 8. Biomed Pharmacother. 2023. PMID: 37816303 Free article.
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.
Ho P, Melms JC, Rogava M, Frangieh CJ, Poźniak J, Shah SB, Walsh Z, Kyrysyuk O, Amin AD, Caprio L, Fullerton BT, Soni RK, Ager CR, Biermann J, Wang Y, Khosravi-Maharlooei M, Zanetti G, Mu M, Fatima H, Moore EK, Vasan N, Bakhoum SF, Reiner SL, Bernatchez C, Sykes M, Mace EM, Wucherpfennig KW, Schadendorf D, Bechter O, Shah P, Schwartz GK, Marine JC, Izar B. Ho P, et al. Among authors: schadendorf d. Cancer Cell. 2023 Jul 10;41(7):1207-1221.e12. doi: 10.1016/j.ccell.2023.05.014. Epub 2023 Jun 15. Cancer Cell. 2023. PMID: 37327789
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher SB, Pedde AM, Hermann CD, Elewaut A, Knolle M, Ramsauer L, Rudolph TJ, Grassmann S, Öllinger R, Kirchhammer N, Trefny M, Anton M, Wohlleber D, Höchst B, Zaremba A, Krüger A, Rad R, Obenauf AC, Schadendorf D, Zippelius A, Buchholz VR, Schraml BU, Böttcher JP. Bayerl F, et al. Among authors: schadendorf d. Immunity. 2023 Jun 13;56(6):1341-1358.e11. doi: 10.1016/j.immuni.2023.05.011. Immunity. 2023. PMID: 37315536 Free article.
Interdisciplinary management of skin cancer.
Rudolph V, Leven AS, Eisenburger R, Schadendorf D, Wiegand S. Rudolph V, et al. Among authors: schadendorf d. Laryngorhinootologie. 2024 May;103(S 01):S100-S124. doi: 10.1055/a-2171-4570. Epub 2024 May 2. Laryngorhinootologie. 2024. PMID: 38697144 Free article. Review. English, German.
Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
Garbe C, Forsea AM, Amaral T, Arenberger P, Autier P, Berwick M, Boonen B, Bylaite M, Del Marmol V, Dreno B, Fargnoli MC, Geller AC, Green AC, Greinert R, Hauschild A, Harwood CA, Hoorens I, Kandolf L, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Lim HW, Longo C, Malvehy J, Moreno D, Pellacani G, Peris K, Robert C, Saiag P, Schadendorf D, Peter Soyer H, Stockfleth E, Stratigos A, Uhara H, Vieira R, Volkmer B, Weinstock MA, Whitaker D, Zalaudek I, Whiteman DC, Brochez L. Garbe C, et al. Among authors: schadendorf d. Eur J Cancer. 2024 Apr 24;204:114074. doi: 10.1016/j.ejca.2024.114074. Online ahead of print. Eur J Cancer. 2024. PMID: 38691877 Free article.
Patients' and dermatologists' preferences in AI-driven skin cancer diagnostics: prospective multicentric survey study.
Haggenmüller S, Maron RC, Hekler A, Krieghoff-Henning E, Utikal JS, Gaiser M, Müller V, Fabian S, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, Weichenthal M, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Kaminski K, Doppler A, Bucher T, Brinker TJ. Haggenmüller S, et al. Among authors: schadendorf d. J Am Acad Dermatol. 2024 Apr 24:S0190-9622(24)00649-2. doi: 10.1016/j.jaad.2024.04.033. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38670313 Free article. No abstract available.
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, Smit DJ, Hansen I, Abeck F, Schadendorf D, Eggermont A, Puig S, Hauschild A, Gebhardt C. Kött J, et al. Among authors: schadendorf d. Eur J Cancer. 2024 May;202:113989. doi: 10.1016/j.ejca.2024.113989. Epub 2024 Mar 8. Eur J Cancer. 2024. PMID: 38518535 Free article. Review.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Schadendorf D, et al. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. J Immunother Cancer. 2024. PMID: 38485189 Free PMC article. Clinical Trial.
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Albrecht LJ, et al. Among authors: schadendorf d. Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38484692 Free article.
1,075 results